Story thread · 2 reports / 2 sources
CAR-T Therapy Shows Durable Benefits in Myasthenia Gravis
medpagetoday.com · 3h
(MedPage Today) -- Mivocabtagene autoleucel (miv-cel), an autologous CD19 chimeric antigen receptor (CAR)-T cell therapy, showed benefits lasting 6 months or longer for generalized myasthenia gravis patients in the phase II portion of the KYSA...
First report: J&J presents two-year data on IMAAVY for myasthenia gravis — investing.com, 1d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.